<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6675</article-id>
      <article-id pub-id-type="doi">10.51847/619nu6lRuI</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinical and Experimental Substantiation of The Use of Macrolide Antibiotic in Gastrointestinal and Respiratory Diseases</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>08</day>
        <month>04</month>
        <year>2023</year>
      </pub-date>
      <volume>14</volume>
      <issue>1</issue>
      <fpage>93</fpage>
      <lpage>99</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>The overpopulation of the planet, especially the increased population density of large cities in developed countries, inevitably leads to the rapid spread of various diseases. Treatment of respiratory and gastrointestinal diseases is almost impossible without the use of antibiotics. Thus, various viruses develop resistance to the action of certain antibiotics. Today, one of the most pressing problems in the market of pharmacological drugs is the development and production of new types of antibiotics. This article discusses the properties of a new macrolide-type antibiotic novomycin. Macrolides are one of the most commonly used antibiotics in adults and children. Their action mechanism is a violation of protein production inside the microbial cell. In scientific work on the example of laboratory animals, studies of acute and chronic toxicity of the drug novomycin, allergic effects on the skin, and the effect of the drug on the course of pregnancy and fetal pathology were carried out. In addition, the antimicrobial activity of novomycin was analyzed. Antimicrobial activity studies have shown that the protection index of novomycin when used 3 hours before infection in white mice was 63% for bordetella infection; 44% for salmonella infection; 56% for pasteurellosis; 80% for staphylococcal infection. Conclusions are made about the effectiveness and safety of the drug.</p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>